Influence of Proteins on the Bioavailability of Carotenoids
CAROPROT
1 other identifier
interventional
24
1 country
1
Brief Summary
A postprandial intervention study is conducted on healthy male subjects to evaluate whether the addition of proteins (why protein isolate, soy protein) can help to increase the bioavailability of carotenoids from a tomato/carrot beverage.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Oct 2019
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 8, 2019
CompletedFirst Posted
Study publicly available on registry
September 6, 2019
CompletedStudy Start
First participant enrolled
October 11, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2021
CompletedSeptember 23, 2021
September 1, 2021
1.7 years
August 8, 2019
September 16, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Concentration of carotenoids in plasma triacyl-rich-lipoprotein (TRL) fraction
Carotenoid concentration (lycopene, beta-carotene) studied over 10 hours postprandial (area-under curve of concentration vs. time)
10 hours postprandial, measured on 3 test clinical test days after test meal intake, interspersed by 1 week each
Secondary Outcomes (3)
Time of maximum concentration of lycopene and beta-carotene and triglycerides in plasma-TRL fraction
10 hours postprandial, measured on 3 clinical test days after test meal intake, interspersed by 1 week
Maximum concentration of lycopene and beta-carotene and triglycerides in plasma-TRL fraction
10 hours postprandial, measured on 3 test clinical days after test meal intake, interspersed by 1 week
Fecal degradation products of carotenoids
Collection covering the test meal intake period, starting from the excretion of a brilliant blue capsule taken the 12 hours before test meal intake, until complete excretion of a second brilliant blue capsule taken 24 hours after test meal intake
Study Arms (3)
Dietary intervention
EXPERIMENTALIntervention with test meal only
Dietary intervention 2
EXPERIMENTALIntervention with test meal and whey protein isolate (30 g)
Dietary intervention 3
EXPERIMENTALIntervention with test meal and soy protein (30 g)
Interventions
Test meals will be served to the subjects, containing soy protein isolate: 350 mL carrot/tomato juice (50:50, v/v), with 30 g added soy protein, plus 5 ml peanut oil as morning test meal, served together with 40 g toasted bread and 20 g of cream-cheese plus 10 g margarine.
Test meals will be served to the subjects, containing soy protein isolate: 350 mL carrot/tomato juice (50:50, v/v), with 30 g added whey protein isolate, plus 5 ml peanut oil as morning test meal, served together with 40 g toasted bread and 20 g of cream-cheese plus 10 g margarine.
Test meals will be served to the subjects, containing soy protein isolate: 350 mL carrot/tomato juice (50:50, v/v), plus 5 ml peanut oil as morning test meal, served together with 40 g toasted bread and 20 g of cream-cheese plus 10 g margarine.
Eligibility Criteria
You may qualify if:
- healthy and free living;
- men;
- age between 20 and 50 years old;
- Body-Mass-Index (BMI) \<30 kg/m2
- non-smokers (abstinent for more than 2 years);
You may not qualify if:
- suffering from any metabolic disease that may cause digestive disturbances (such as Crohn's disease or colitis);
- malabsorption disorders;
- BMI over 30 kg/m2;
- hyperlipidaemia (triglycerides and total cholesterol over 200 mg/dl)
- any individuals following a special diet that is not compatible with wash-out periods or test meals (vegetarian, gluten-free or diabetic);
- regular consumption of more than 5 portions (80-100 g) of fruits and vegetables per day;
- being on medical treatment or consuming any medication for chronic conditions or recent illness (e.g. antibiotics);
- consuming regularly dietary supplements;
- abnormally high or low values of plasma circulating carotenoids;
- tobacco smoking;
- frequent alcohol consumption (over 2 glasses per day);
- food allergies or intolerances that are not compatible with test meals (e.g. gluten or milk intolerance);
- daily practice of intense physical activity of 120 min or more.
- No special population group such as prisoners, children, the mentally disabled or groups whose ability to give voluntary informed consent may be in question, will be recruited for this study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Luxembourg Institute of Healthlead
- Laboratoires Réuniscollaborator
- Université Catholique de Louvaincollaborator
- Luxembourg Institute of Science and Technologycollaborator
Study Sites (1)
Luxembourg Institute of Health
Strassen, 1445, Luxembourg
Related Publications (3)
Iddir M, Degerli C, Dingeo G, Desmarchelier C, Schleeh T, Borel P, Larondelle Y, Bohn T. Whey protein isolate modulates beta-carotene bioaccessibility depending on gastro-intestinal digestion conditions. Food Chem. 2019 Sep 1;291:157-166. doi: 10.1016/j.foodchem.2019.04.003. Epub 2019 Apr 1.
PMID: 31006454BACKGROUNDSoukoulis C, Bohn T. A comprehensive overview on the micro- and nano-technological encapsulation advances for enhancing the chemical stability and bioavailability of carotenoids. Crit Rev Food Sci Nutr. 2018 Jan 2;58(1):1-36. doi: 10.1080/10408398.2014.971353. Epub 2017 Jul 5.
PMID: 26065668BACKGROUNDCorte-Real J, Guignard C, Gantenbein M, Weber B, Burgard K, Hoffmann L, Richling E, Bohn T. No influence of supplemental dietary calcium intake on the bioavailability of spinach carotenoids in humans. Br J Nutr. 2017 Jun;117(11):1560-1569. doi: 10.1017/S0007114517001532. Epub 2017 Jun 27.
PMID: 28651681RESULT
Related Links
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Torsten Bohn, PhD
Luxembourg Institute of Health
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- BASIC SCIENCE
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER GOV
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 8, 2019
First Posted
September 6, 2019
Study Start
October 11, 2019
Primary Completion
June 30, 2021
Study Completion
June 30, 2021
Last Updated
September 23, 2021
Record last verified: 2021-09
Data Sharing
- IPD Sharing
- Will not share
Data of subjects will not be available for outside researchers.